Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 3
2003 1
2005 1
2006 1
2009 1
2014 3
2015 6
2016 1
2018 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E. Buhl R, et al. Among authors: korducki l. Eur Respir J. 2015 Jun;45(6):1763. doi: 10.1183/09031936.50136014. Eur Respir J. 2015. PMID: 26028626 Free PMC article.
Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease.
Troosters T, Maltais F, Leidy N, Lavoie KL, Sedeno M, Janssens W, Garcia-Aymerich J, Erzen D, De Sousa D, Korducki L, Hamilton A, Bourbeau J. Troosters T, et al. Among authors: korducki l. Am J Respir Crit Care Med. 2018 Oct 15;198(8):1021-1032. doi: 10.1164/rccm.201706-1288OC. Am J Respir Crit Care Med. 2018. PMID: 29664681 Clinical Trial.
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E. Buhl R, et al. Among authors: korducki l. Eur Respir J. 2015 Apr;45(4):969-79. doi: 10.1183/09031936.00136014. Epub 2015 Jan 8. Eur Respir J. 2015. PMID: 25573406 Free PMC article. Clinical Trial.
A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, Fogarty C. Maleki-Yazdi MR, et al. Among authors: korducki l. Respir Med. 2015 May;109(5):596-605. doi: 10.1016/j.rmed.2015.02.012. Epub 2015 Mar 3. Respir Med. 2015. PMID: 25829298 Free article. Clinical Trial.
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P. Koch A, et al. Among authors: korducki l. Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. doi: 10.2147/COPD.S62502. eCollection 2014. Int J Chron Obstruct Pulmon Dis. 2014. PMID: 25045258 Free PMC article. Clinical Trial.
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
Joos GF, Aumann JL, Coeck C, Korducki L, Hamilton AL, Kunz C, Aalbers R. Joos GF, et al. Among authors: korducki l. Respir Med. 2015 May;109(5):606-15. doi: 10.1016/j.rmed.2015.02.005. Epub 2015 Feb 14. Respir Med. 2015. PMID: 25776199 Free article. Clinical Trial.
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
McGarvey L, Niewoehner D, Magder S, Sachs P, Tetzlaff K, Hamilton A, Korducki L, Bothner U, Vogelmeier C, Koch A, Ferguson GT. McGarvey L, et al. Among authors: korducki l. COPD. 2015;12(5):484-93. doi: 10.3109/15412555.2014.991864. Epub 2015 Feb 18. COPD. 2015. PMID: 25692310 Free PMC article. Clinical Trial.
19 results